Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
GLP-1: The trusted option with a proven track record for sustained weight loss, cardiovascular protection, and long-term health benefits
Each targets similar metabolic pathways while offering patients flexibility in administration and dosing
At week 68, mean bodyweight change was 14.9% down with semaglutide and 2.4% down with placebo, an estimated treatment difference of 12.4 percentage points
Activated MEK1/2 then activates ERK1/2 (MAPK)
Possibly adding a new entrant to the highly competitive diabetes/weight loss market, Roche has announced positive interim results from an ongoing Phase I trial for its oral small molecule GLP-1 receptor agonist, CT996
LGKCYLWS2022039)
US$ 21.10
US$ 25.82
US$ 29.05
